Omeros Corporation (OMER)
NASDAQ: OMER
· Real-Time Price · USD
9.83
-0.59 (-5.66%)
At close: Oct 16, 2025, 3:59 PM
9.70
-1.32%
After-hours: Oct 16, 2025, 07:59 PM EDT
-5.66% (1D)
| Bid | 9.65 |
| Market Cap | 668.99M |
| Revenue (ttm) | 412K |
| Net Income (ttm) | -122.47M |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -4.17 |
| Forward PE | -58.57 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.81 |
| Volume | 11,054,011 |
| Avg. Volume (20D) | 3,053,959 |
| Open | 9.15 |
| Previous Close | 10.42 |
| Day's Range | 8.95 - 10.36 |
| 52-Week Range | 2.95 - 13.60 |
| Beta | 2.33 |
| Ex-Dividend Date | n/a |
About OMER
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OMER
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OMER stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsOmeros Corporation is scheduled to release its earnings on
Nov 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+154.15%
Omeros shares are trading higher after the company...
Unlock content with
Pro Subscription
7 months ago
+3.89%
Omeros shares are trading after the company announced results for its narsoplimab expanded access program.
16 hours ago · seekingalpha.com
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull CaseOmeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bank...
